3D Systems Corporation — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. The filing also reports unaudited fourth-quarter results. Amounts are in U.S. dollars; financial figures are in millions unless noted otherwise.
Business context
3D Systems provides 3D printers, print materials, software, custom manufacturing services, and healthcare simulation and personalized medical solutions. Its business spans products, materials, and services, with operations across the Americas, EMEA, and Asia Pacific. No customer represented more than 10% of revenue.
Key financial metrics
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $653.7 | $513.4 |
| Gross profit / margin | $317.4 / 48.6% | $267.6 / 52.1% |
| Operating income / margin | $26.3 / 4.0% | $80.9 / 15.8% |
| Net income attributable to 3D Systems | $11.6 | $44.1 |
| Basic and diluted EPS | $0.11 | $0.45 |
| Operating cash flow | $51.1 | $25.2 |
| Cash and cash equivalents at year-end | $284.9 | $306.3 |
| Working capital at year-end | $432.2 | $416.4 |
Fourth-quarter revenue was $187.4, up from $154.8 a year earlier; gross profit was $89.8, operating income $4.2, and net income attributable to 3D Systems $1.6. Fourth-quarter gross margin was approximately 47.9%, versus 51.7% in Q4 2013; EPS was $0.01 versus $0.11.
FY 2014 revenue by management’s categories was products $283.3, materials $158.9, and services $211.5. Healthcare revenue increased 80.3% to $129.3, or 19.8% of total revenue. Organic revenue growth was 13.3% for the full year and 7.2% in Q4.
Cash used in investing activities was $375.4, including $345.4 for acquisitions and $22.7 in capital expenditures. Financing activities provided $308.6, primarily from $299.7 in net proceeds from common-stock issuance. Cash declined $21.5 during the year. The company had $9.4 of capitalized lease obligations at year-end; its $150.0 revolving credit facility was undrawn, and the convertible notes had been fully converted.
Material changes versus prior year
- Revenue rose 27.3%, with growth across products, materials, and services. Acquisitions contributed significantly; full-year organic growth was 13.3%, down from 29.4% in 2013.
- Gross margin fell 3.5 percentage points to 48.6%, reflecting product and sales mix, manufacturing ramp-up, and new-product start-up costs. Product gross margin fell to 35.9% from 44.7%.
- Operating expenses increased 55.9% to $291.1, including SG&A of $215.7 and R&D of $75.4. Stock-based compensation rose to $32.8 and depreciation and amortization to $55.2.
- Operating income declined to $26.3 from $80.9, and net income attributable to the company fell to $11.6 from $44.1, despite higher revenue and gross profit.
- Accounts receivable rose $56.0 and inventory rose $30.8; days sales outstanding increased to 83 from 79. Management cited greater reseller and retailer sales on credit terms, order timing, and expanded inventory needs.
- Cash outlays for acquisitions more than doubled to $345.4. The company completed ten acquisitions, including Medical Modeling, Simbionix, LayerWise, Robtec, and botObjects.
Outlook, risks, and unusual items
- No specific revenue, earnings, or margin guidance is provided. Management’s strategy emphasizes manufacturing, metals, medical, materials, and mainstream/consumer markets, through internal development and selective acquisitions.
- Cimatron’s acquisition, announced in 2014, closed on February 9, 2015 for approximately $77 million net of cash. The filing describes expected strategic benefits but does not quantify them.
- Key stated risks include acquisition integration and execution, rapid technology change and competition, pressure on pricing and margins, reliance on limited suppliers, foreign exchange exposure, product quality and liability, and the ability to manage rapid growth.
- Goodwill was $589.5 and other intangible assets were $251.6 at year-end. No goodwill or long-lived-asset impairment was recorded, but impairment testing relies on estimates and future performance.
- Foreign-currency transaction losses were $5.7 in 2014; foreign-currency translation losses contributed to a $30.3 other comprehensive loss. Management estimated a hypothetical 10% exchange-rate change could affect revenue by about $32.0.
- Non-GAAP net income was $75.1 and adjusted EPS was $0.70, versus GAAP net income of $11.6 and EPS of $0.11. The adjustments exclude, among other items, acquisition-related amortization and expenses and stock-based compensation.
- The Formlabs patent dispute was settled under a license agreement providing for an 8% royalty on net sales of licensed products. The company said other legal matters were not expected to materially affect results or financial position.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Investor verification points
- Assess whether organic growth and demand trends can sustain revenue growth as organic growth slowed and acquisitions became a major contributor.
- Track gross-margin recovery, particularly product margins, and whether elevated operating expenses and R&D investment translate into profitable growth.
- Review acquisition integration, purchase-price allocations, earnouts, and expected returns; goodwill and intangible assets increased substantially.
- Monitor collections, receivables aging, bad-debt allowances, and inventory levels; receivables over 90 days past due rose to 16.7% from 9.1%.
- Evaluate dilution from equity financing and stock compensation, and the company’s cash needs for acquisitions, capital expenditures, and operating commitments.
- Confirm the current status and terms of the revolving credit facility, acquisition commitments, and the potential subsidiary put obligation estimated at $8.9 million.